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ABSTRACT 
Malaria is a disease caused by parasites of the genus Plasmodium. Five species cause 
human disease, but the most common in tropical areas, and the cause of severe disease 
is Plasmodium falciparum. Control of morbidity and mortality is mainly achieved 
through appropriate malaria case management, which includes prompt diagnosis and 
treatment with effective antimalarial drugs. While definitive diagnosis of malaria is 
made by demonstration of parasites in the patient blood through microscopic 
examination of giemsa stained blood smears, in most clinical settings in Africa, 
diagnosis is limited by lack of facilities and personnel. The availability of malaria rapid 
diagnostic tests (RDTs) offers an opportunity to extend diagnostic services to areas 
previously not covered by conventional microscopy services. 
 
Two intervention trials were conducted, one at primary health care (PHC) facilities 
using microscopy, and the other at community level, through community health 
workers (CHWs), using rapid diagnostic tests (RDTs) for malaria diagnosis, and the 
impact of the interventions on antimalarial drugs prescription practices, antibiotic 
prescriptions and health outcome was investigated (Study I and II). A descriptive, cross 
sectional study was conducted to assess health workers diagnostic and prescription 
practices following introduction of RDTs for universal testing of malaria at PHC level 
in Tanzania (Study III). An exploratory study was also carried out to assess the 
usefulness of Histidine rich protein 2 (HRP2) and lactate dehydrogenase (LDH) based 
RDTs for treatment monitoring and detection of recurrent infection following 
artemisinin-based combination therapy (ACT) during a 42 day follow up period (Study 
IV).   
 
The use of parasite-based diagnostics significantly reduced antimalarial prescriptions at 
health facility and community level without affecting the health outcome of patients not 
treated with antimalarials (study I and II). The prescriptions of antimalarial drugs were 
61% at intervention health facilities, whereas in the clinical and control arms the 
prescription rates remained high, 95% and 99%, respectively (study I). Similarly, 53% 
of patients tested with RDT at community level were provided antimalarial drugs 
compared to 96% among patients treated based on clinical diagnosis only (Study II). 
The availability of parasite-based diagnostics and antimalarial drugs within the 
community allowed early access to treatment as 67% of patients consulted CHWs 
within 24 hours of onset of fever (Study II). The rate of non adherence to test results 
was low in both study I and II.  
 
Study III observed low use of parasite-based diagnostics among fever patients (63%), 
low non adherence to test results (14%), substantial prescription of antimalarial drugs to 
non-tested patients (28%) and high prescriptions of antibiotics among patients with 
negative RDT results (81%), as well as frequent stock outs of both RDTs and ACTs.  
 
  
HRP2 based tests performed poorly when compared to LDH based tests for treatment 
monitoring, with median clearance times of 28 (7-42) and 7 (2-14) days respectively 
(Study IV). HRP2 based tests were unable to detect 8/10 recurrent infections during 
follow up compared to only two recurrent infections missed by LDH based tests.  
 
These studies lead to a conclusion that the availability of parasite-based diagnostics 
helps to restrict treatment with antimalarial drugs to patients with malaria. However, 
non adherence to malaria test results could undermine the potential of RDTs, and in-
depth studies should be conducted to identify its causes. As the relative contribution of 
malaria as a cause of fever is declining in Tanzania, there is need to improve the overall 
management of non-malarial fevers. The longer persistence of HRP2 antigen in blood 
makes HRP2 based tests not suitable for treatment monitoring and detection of 
recurrent infection calling for alternative diagnostic strategies for this purpose.  
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1 INTRODUCTION 
1.1 General introduction to malaria 
The global health burden from malaria has been declining in recent years (1,2). 
Globally, mortality due to malaria has declined by 45% between 2000 and 2012; with 
an estimated 207 million cases and 627,000 deaths in 2012 (1). The majority of these 
deaths (91%) occur in Africa, and 86% of them in children under five years of age 
(3,4). The decline in the burden of malaria has been attributed to the use of artemisinin-
based combination therapy (ACT), and the scale up of other malaria control measures 
mainly the use of long lasting insecticide treated nets (LLNs) and indoor residual 
spraying (IRS).  
 
1.1.1 Malaria parasites 
Malaria is a disease caused by protozoan parasites of the genus Plasmodium, first 
described by Charles Laveran in 1880 (5). There are over 120 species of plasmodia 
infecting the blood of mammals, reptiles and birds. Four species are the most common 
and important cause of disease in humans, namely Plasmodium falciparum, P. 
malariae, P. ovale and P. vivax (6). A fifth species, Plasmodium knowlesi, a parasite of 
monkeys is now considered a human parasite as it is naturally transmitted to humans 
(7,8). Plasmodium falciparum, P. malariae, P. ovale and P. vivax are widely distributed 
in the tropics and subtropics, while P. knowlesi is confined to Malaysia and Borneo in 
South East Asia. Plasmodium falciparum is common in the tropics and subtropics, and 
is the chief infection in endemic areas of Africa. However, mixed species infections are 
also common in endemic areas, with P. falciparum and P. malariae or P. ovale in 
tropical Africa and P. falciparum and P. vivax in subtropical areas.  
 
1.1.2 Malaria transmission 
Natural transmission of malaria occurs through the vector, mosquitoes of the genus 
Anopheles. The discovery that mosquitoes are involved in the transmission of malaria 
was made by Ronald Ross in 1897 (5).There are about 430 species of Anopheles, 70 of 
which transmit malaria and only 40 are of importance (9). The most important vector of 
malaria in Africa belongs to the Anopheles gambiae sensu lato (s.l.) complex (A. 
gambiae sensu stricto [s.s.]), A. arabiensis, A. melas and A. merus) and Anopheles 
funestus.  Anopheles gambiae s.s. and A. funestus are more widespread, while A. melas 
and A. merus are confined to coastal areas of West and East Africa, respectively. Only 
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female anopheles mosquitoes are vectors of human malaria, taking a blood meal to 
provide for nutrients and maturation of eggs, and hence facilitating transmission from 
one host to another. The feeding and resting behaviours of mosquitoes determine their 
efficiency as vectors of malaria (9). 
 
Transmission is also possible through blood transfusion from an infected donor, from 
mother to foetus through the placenta, and through accidental puncture with an infected 
needle. 
 
1.1.3 Life cycle of malaria parasites 
Plasmodium is a two host parasite, with female Anopheles mosquitoes as definitive 
hosts and humans as intermediate hosts (6). The life cycle of malaria parasites is 
described in Figure 1. Briefly, sporozoites are the infective stage to humans, inoculated 
through the bite of an infected female anopheles. Within an hour, they disappear from 
circulation and enter parenchyma cells of the liver where they divide and multiply 
(schizogony) to form exoerythrocytic schizonts. The liver schizont, with thousands of 
merozoites eventually bursts to release free individual merozoites, which are shed into 
peripheral blood. The duration of the exoerythrocytic cycle varies between 5 and 16 
days, depending on species of parasite (6). 
 
With P. vivax and P. ovale, some of the sporozoites which invade parenchyma cells of 
the liver differentiate into hypnozoites, which remain dormant for long periods and 
resume growth at a later time with subsequent release of merozoites into circulation and 
continuation of the erythrocytic cycle (6). Hypnozoites are the true cause of relapses. 
 
Merozoites invade erythrocytes to start the erythrocytic cycle. Within the erythrocytes, 
the parasite is transformed into a ring form, the trophozoite, with a nucleus and 
cytoplasm surrounding a vacuole. The trophozoite feeds on haemoglobin and enlarges 
to form the erythrocytic schizont. It undergoes division (Schizogony) to form daughter 
parasites (merozoites). The infected erythrocyte eventually ruptures to release 
merozoites, which invade other erythrocytes to start the cycle all over. When infected 
erythrocytes rupture, in addition to merozoites, they also release residual debris, which 
is toxic to the host. The toxins stimulate the release of cytokines, the cause of fever. 
The duration of the erythocytic schizogony cycle is 48 hours in P. falciparum, P. ovale 
and P. vivax; 72 hours in P. malariae and 24 hours for P. knowlesi  (6,8,10). This 
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duration is linked to the fever pattern observed with infection of the different species, 
referred to as tertian for P. falciparum, P. ovale and P. vivax, quartan for P. malariae 
and quotidian for P. knowlesi. 
 
Figure 1: The life cycle of malaria parasites.  
 
 
Source:  http://www.niaid.nih.gov/topics/malaria/pages/lifecycle.aspx    
 
Some of the merozoites develop into sexual forms, the male and female gametocytes, 
which do not divide in the human host. When ingested by a suitable female Anopheles 
mosquito with a blood meal, the male gametocyte undergoes exflagellation to produce 
eight flagellated gametes. The female gametocyte frees itself from the erythrocyte 
membrane to become a female gamete. Fertilization takes place to form a zygote, 
which enlarges and becomes motile, the ookinete. The ookinete penetrate an epithelial 
cell lining the stomach wall and starts to develop and divide to form the oocyst on the 
outer wall of the stomach. Divisions within the oocyst (sporogony) continue to produce 
slender pointed forms called Sporozoites. The oocyst eventually raptures to release 
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sporozoites, some of which find their way into salivary gland and hence the saliva. 
Sporozoites are injected into the next human host when the mosquito takes a blood 
meal. Development in the mosquito takes 10 to 15 days depending on species, with P. 
malariae taking the longest time (6). 
 
The number of merozoites produced by the exoerythrocytic and erythrocytic schizonts 
differ between species. Morphological characteristics of the erythrocytic stages also 
differ, and are used in species identification through microscopic examination of thin 
blood smears.  
 
1.1.4 Clinical presentation of malaria 
The first physician to describe the clinical features of malaria was Hippocrates in the 5
th
 
century BC, and later on, the name ‘malaria’ was given by Italians due to its association 
with foul air in marsh areas around Rome (5). At that time, the causative agent of the 
disease had not been discovered. 
 
Malaria is an acute febrile illness whose features can vary from mild to severe, also 
referred to as uncomplicated and severe malaria. The severity of the illness depends on 
the parasite species involved, the patient’s immune status, the intensity of the infection, 
and the presence of accompanying conditions, with P. falciparum and P. knowlesi 
being able to cause fatal disease.  
 
The most common feature of malaria is fever. Patients may experience flu-like 
symptoms before the fever sets in. The fever paroxysm starts with a high temperature, 
followed by chills, shivering and eventually sweating. Other symptoms are non specific 
and include headache, joint pain, malaise, body weakness, vomiting, diarrhoea, chest 
pain, poor appetite, anaemia and spleenomegally (11).  
 
According to the WHO, a patient is considered to have severe malaria if there is P. 
falciparum asexual parasitemia and no other cause of symptoms, and the presence of 
one or more of the following symptoms: impaired consciousness, severe anaemia, 
multiple convulsions, circulatory collapse, abnormal bleeding, haemoglobinuria, 
jaundice, renal dysfunction, pulmonary oedema, prostration, and respiratory distress 
(12,13). Severe malaria, especially that due to P. falciparum is life threatening, and if 
there is delay in treatment, it can lead to serious complications and death (12,14). While 
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everybody is potentially at risk of infection due to malaria parasites, non immunes such 
as visitors to endemic areas and young children and pregnant women in endemic areas 
are at a higher risk of developing severe disease. 
 
P. falciparum is the most pathogenic, causing the most severe disease and is 
responsible for almost all deaths attributed to malaria. This is mainly due to production 
of a large number of merozoites per liver schizont, ability to infect young and mature 
red blood cells and produce a large number of erythrocytic merozoites, destruction of 
infected and uninfected red blood cells by the spleen causing anaemia, the tendency to 
clump together around infected erythrocytes and sequestration of parasitized cells in 
blood vessels and adherence to internal organs such as the placenta and brain (6,15). 
 
 
1.2 MALARIA DIAGNOSIS AND TREATMENT 
Since malaria is an illness that may rapidly progress to severe disease and even death, 
early diagnosis and prompt treatment of acute malaria episodes is an important strategy 
to reduce morbidity and mortality (11). The first and most important role of diagnosis is 
in patient management. Diagnosis helps to identify the causative agent of the illness so 
that the patient may receive appropriate treatment. The early identification of malaria 
negative patients allows for investigation and appropriate treatment of other causes of 
fever (16). By identifying malaria cases and limiting treatment to infected patients only, 
diagnosis also helps in rational use of antimalarials drugs (17,18). Diagnosis also plays 
a role in treatment monitoring and identification of drug resistance. In some settings, it 
might be necessary to identify asymptomatic infections that may need to be treated. 
Diagnosis is also useful in surveillance, to monitor the impact of interventions (19). 
When used to guide patient management, a diagnostic strategy must have high 
sensitivity to ensure that all true cases are detected and treated, as well as high 
specificity to avoid false positives and unnecessary antimalarial treatment with a 
possibility of overlooking the true cause of the illness (16,20). A description of the 
different diagnostic strategies used for malaria diagnosis is presented below. 
 
1.2.1 Clinical diagnosis 
The diagnosis of malaria may be suggested by clinical features described by the patient, 
the most common of which is fever. In many parts of Africa where malaria is endemic, 
absence of laboratory services lead to treatment of malaria based on clinical symptoms, 
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especially the presence or history of fever. However, there are similarities in the 
presentation of malaria and other causes of fever such as pneumonia, flue, typhoid, etc. 
such that clinical features alone cannot predict a diagnosis of malaria and often lead to 
over-prescription with antimalarials (21). Even the WHO/UNICEF Integrated 
Management of Childhood Illnesses Algorithm (IMCI) developed to improve the 
accuracy of clinical diagnosis has been found inadequate in diagnosing malaria (22–
24). Although the IMCI algorithm was aimed at identifying as many cases of 
potentially fatal illness as possible using simple diagnostic criteria, it had the 
disadvantage of leading to over-treatment with both antimalarials and antibiotics. Based 
on clinical symptoms and the IMCI algorithm, a large proportion of patients were 
diagnosed as having malaria and treated with antimalarial drugs while only a small 
proportion were actually parasite positive (25–27). 
 
A review of published studies on algorithms for diagnosing malaria concluded that in 
areas where malaria is highly prevalent, the algorithms are highly sensitive but not 
specific enough to direct treatment, and they are also area specific (28). However, 
treatment of all febrile children in highly endemic areas with antimalarial drugs lacking 
laboratory support was considered appropriate, and the algorithms could also be used as 
a screening tool to reduce the number of patients requiring microscopy.  
 
Malaria diagnosis requires a criteria or test that is highly sensitive and specific, to 
reduce the chance of missed and untreated infections which could progress to severe 
disease and death while also reducing over-diagnosis and over treatment with 
antimalarial drugs.  It was therefore suggested that in order to prevent over-prescription 
and inappropriate treatment, and the rapid development of resistance to new first line 
anti-malarial drugs, clinical diagnosis should be supplemented by microscopy (28). 
 
1.2.2 Laboratory diagnosis 
Since clinical diagnosis is not specific, not being able to tell if the illness is due to 
malaria parasites or non malaria causes, definitive malaria diagnosis is usually achieved 
by demonstrating the presence of parasites in the blood of patients.  
 
1.2.2.1 Microscopy 
While the use of the microscope in biology was first reported during the 17 century 
(29), the first successful attempt to identify malaria parasites in blood of infected 
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patients was made by Charles Laveran in 1880 (CDC, 2012). Through careful 
observation while examining fresh unstained blood, he was able to identify malaria 
parasites. Further studies of the parasite were facilitated by the development of better 
staining methods. 
 
The Giemsa staining method 
The technique carries the name of Gustav Giemsa, who developed the stains during the 
late 1880s (30). The giemsa stain is a mixture of acidic and basic dyes and its principle 
components include Azure B, methylene blue and eosin. The stain is able to achieve 
differential staining of the parasite, with the nucleus staining red and cytoplasm blue. 
Under most circumstances, the stain is purchased as powder or stock solution. The 
procedure for preparation and staining of blood films is explained in detail elsewhere  
(31) and is briefly described here. A dilute working solution (5 or 10%) prepared from 
the stock solution is used for staining of blood smears and this has to be changed daily. 
The duration of staining depends on the concentration of the working solution. Thick 
and thin blood smears prepared from capillary or venous blood are air dried. The thin 
film is fixed prior to staining to preserve the morphology of parasites and red blood 
cells, an important aspect in species identification. The thick film, which uses a larger 
volume of blood  has higher sensitivity for detecting parasitemia, while the thin film is 
for confirming the infecting species (18,32). Quantification of parasites can also be 
done using both types of smears. Microscopic examination of Giemsa stained blood 
smears is still used as a yardstick against which other tests are measured (30,32).  
 
The performance of blood slide microscopy requires the availability of a good quality 
microscope, good quality consumables, a light source and well-trained personnel. In the 
hands of a well-trained and experienced technician, blood slide microscopy has a high 
sensitivity and specificity (32). Expert microscopy can detect as low as 5-10 
parasites/µL of blood (17), while under routine conditions the detection level is 50-100 
parasites/µL. It is also informative, being able to identify the infecting species, the 
circulating stages and detect morphological changes induced by drug treatment. In 
addition to that, parasite densities can be quantified and used to indicate severity or 
assess parasitological response to treatment. It is also relatively inexpensive with low 
operational costs, and the microscope can be shared with other disease control 
programmes such as tuberculosis, sexually transmitted infections and intestinal 
infections.  
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The disadvantages of blood slide microscopy include the fact that it is labour intensive 
and time consuming, taking about an hour to produce results, and its dependence on 
well-trained and supervised technicians and availability of electricity (33–35). Its 
accuracy depends on parasite density, being unable to detect very low parasitemia 
levels. The standard procedure uses a 5% giemsa solution and staining for 20-30 
minutes. However, this may be reduced to 10 minutes by increasing the stain 
concentration to 10%. 
  
Modifications to the standard giemsa staining of blood slides have been developed, to 
make parasite identification easy, reduce the processing time to produce results, and 
make it possible for people with minimal training to read the slides. These include the 
field staining technique, which utilizes a water based Romanovsky stain composed of 
two solutions and is much faster than the conventional giemsa stain. Others are the 
modified giemsa staining, and fluorescent techniques such as acridine orange and the 
Quantitative Buffy coat (QBC) techniques. 
 
Fast thick smear (FTS)  
A modified giemsa staining technique, the FTS method has been described (36). This 
method, which involves rapid drying, an isotonic fixative and a haemolysing solution 
containing saponin, was evaluated and advantages included reduced drying times 
(using an incubator at 37C) and better smear readability. Parasite detection threshold 
was found to be 5 parasites/L, a level comparable to that achieved with conventional 
thick smear examination by experienced microscopists. Although both the sensitivity 
and specificity of this method were found to be high, the use of saponin and the 
requirement for incubator or microwave for drying renders this test less likely to be 
used in resource poor settings in endemic areas. 
 
Fluorescent techniques 
Acridine orange (AO) 
Staining of thin blood films with acridine orange and examination using fluorescent 
microscopes or light microscope fitted with an interference filter is among the 
modifications evaluated and in use in some places (37,38). The technique uses a 
fluorescent dye with affinity to the nucleic acid in the parasite. The method has 
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shown a sensitivity between 41-93%, with lower sensitivities at low parasite densities 
(35,39).  
The advantages were the short processing times necessary to produce results (10 
minutes), and that even less experienced observers were able to produce good quality 
results. Examination of slides is done at x600. Where fluorescent microscopes are used, 
cost considerations become important. Otherwise ordinary light microscopes fitted with 
an interference filter are adequate and cost effective.  
 
Quantitative buffy coat (QBC) technique 
Another technique is the QBC method, which is also based on acridine orange staining 
in which blood examination is done using a microscope fitted with a UV adapter. In 
this technique, blood is collected into commercially supplied capillary tubes coated 
with the dye, centrifuged for 5 minutes and the buffy coat examined under a 
microscope. A study in Tanzania found the test to have good performance, being faster 
in producing results (in 10 minutes) with a sensitivity of 81.3-100% and specificity of 
86.4-100% (37).  In a study conducted in an outpatient clinic in Kenya comparing 
different diagnostic techniques, a few problems were identified with this method, 
including the breakage of tubes during centrifugation, the difficulty in recognising 
parasites and the fact that quantification of parasites is not possible (40). Other 
structures that fluoresce (Howell Jolly bodies) were also confusing. 
 
1.2.2.2 Molecular techniques 
Molecular techniques are used to detect parasite DNA and RNA in patients’ blood, 
using the principle of nucleic acid hybridization or amplification methods. Earlier 
methods used the hybridization techniques, in which DNA probes directed at repetitive 
sequences of parasite genes were used to detect parasites from a patients' blood on filter 
paper. With availability of PCR amplification, the number of copies of any target 
sequence may be multiplied, providing a way of studying various aspects of the 
parasite, such as genes responsible for antimalarial drug resistance, and for 
differentiating between infecting species. Several modifications of the PCR technique 
have been done such as automation of the thermal recycling used for amplification 
process, separation of the amplified material by agarose electrophoresis and other 
improvements to make the PCR user friendly.  
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The tests are highly sensitive and specific, with threshold of detection of <1 
parasites/μL providing positive results from sub-patent infections (41,42). They are also 
useful in detecting mixed infections. They are now playing an important role in studies 
on drug resistance mutations (43), in clinical trials to assess cure rates with antimalarial 
drugs (44,45), as well as in differentiating recurrences from reinfections (46,47). They 
are also aiding in studying genetic mutations such as deletions of HRP2 and HRP3 
genes which could affect the performance of RDTs (48–50). They are also used for 
quality control of microscopy and for monitoring disease control programmes to assess 
the impact of malaria control interventions. Due to the use of sophisticated and often 
expensive equipment requiring considerable expertise, and taking much longer time to 
produce results, at the moment they are mainly used in research laboratories and 
hospitals in developed countries.  
 
Recent advances in PCR technology are geared at adapting the technique to a variety of 
conditions, including areas lacking sophisticated equipment. One such modification is 
the loop-mediated isothermal amplification (LAMP) which can amplify DNA under 
isothermal conditions (51). The technique is sensitive, fast (taking less than 1 hour) and 
simple; using heat treated blood samples as a template, requiring just a water bath or a 
heat block for carrying out the reaction and inspection with the naked eye or turbidity 
meter, features that makes it suitable for use in clinical settings (52–56).  
 
1.2.2.3 Rapid immunochromatographic tests 
The use of blood slide microscopy has been limited by concerns of the time taken to 
make a diagnosis and the need for well-trained technicians, which makes it difficult to 
maintain quality in poor resource settings (17). Rapid diagnostic tests (RDTs), which 
are immunochromatographic, based on detection of parasite antigen in blood have 
addressed these concerns. There are three main antigens targeted by available RDTs, 
the histidine rich protein 2 (HRP2),  parasite specific lactate dehydrogenase (pLDH) 
and Plasmodium aldolase (33,35).   
HRP2 is a water soluble antigen present in P. falciparum only and is produced by the 
parasite throughout the erythrocytic life cycle and young gametocytes. The antigen is 
secreted by the parasite in the blood, and is detectable in erythrocytes and different 
body fluids including serum, plasma, cerebrospinal fluid and urine. Its main drawback 
   11 
is its persistence in blood for a longer period after clearance of parasites following 
successful therapy (35).  
The LDH antigen is produced by all human species during their growth in the RBC. 
LDH is either species specific such as PfLDH or PvLDH or as Pan-Plasmodium 
LDH, detecting all 5 human malaria species (57). It is cleared from blood at about the 
same time as parasites following successful therapy. Previously, the LDH-based 
RDTs were less sensitive than HRP2-based tests in detection of P. falciparum, and 
were more fragile to high temperature and humidity during storage (58,59). The last 
generation of LDH P. falciparum specific tests based on monoclonal antibodies have 
shown equal sensitivity as the HRP2 based RDTs (60) and are less fragile to exposure 
to high temperature and humidity (61). The third pan-malaria antigen (PMA) targeted 
in RDTs is Aldolase, which is often used in combination with the Pf-specific HRP2.  
RDTs are available in different formats such  as dipsticks, cassettes or cards. Despite 
differences in the target antigen and the format, the tests have the same mechanism of 
action. They are lateral flow devices relying on detection of antigen-antibody 
complex migrating across a nitrocellulose membrane to produce a visible coloured 
line at the immobile phase (Figure 2). Tests detecting one species of parasites will 
have two lines, one test and one control band; while those detecting multiple species 
will have three lines, two test and one control band.  
Evaluation of RDTs have been carried out in different settings, with different patient 
populations, with different malaria species, in environments with differing 
temperature and humidity, in outpatient departments in developed countries as well as 
rural areas with untrained personnel. They have been found to take a shorter time to 
produce results (5-20 minutes), and can be performed by personnel with minimal 
training (62–64). They also show high sensitivity and specificity and are seen as a 
cost effective approach to reduce over-treatment (33,58,65). They indicate presence 
or absence of parasite antigens, and whether the infecting species is Plasmodium 
falciparum or non-falciparum. Their ease of use, requiring neither a technician nor 
equipment or electricity, makes them a promising tool even in resource poor settings. 
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Figure 2: Mechanism of action of Rapid diagnostic tests 
1. Dye-labeled antibody, specific for target antigen, is present on the lower end of nitrocellulose strip or 
in a plastic well provided with the strip. Antibody, also specific for the target antigen, is bound to the 
strip in a thin (test) line, and either antibody specific for the labeled antibody, or antigen, is bound at 
the control line 
 
 
2. Blood and buffer, which have been placed on strip or in the well, are mixed with labeled antibody 
and are drawn up strip across the lines of bound antibody 
 
 
 
3. If antigen is present, some labeled antibody will be trapped on the test line. Excess-labeled antibody 
is trapped on the control line 
 
Source: WHO/FIND/CDC/TDR (2011) Malaria Rapid Diagnostic Test Performance 
Results of WHO product testing of malaria RDTs: Round 3 (2010-2011) 
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However, RDTs are not very informative and do not indicate parasite density. They are 
also less sensitive at low parasite densities (<100 parasites/µL of blood) when 
compared to microscopy and molecular tests. Other problems include the prozone 
phenomenon, deletion of the HRP2 gene and HRP2 antigen persistence. A prozone 
effect which is due to too much antigen has been demonstrated in some cases, leading 
to production of false negative results in patients with very high parasitemia (66,67). 
Finding of parasites with HRP2 deletions and genetic variability of the HRP2 antigen 
are also raising concern on their potential to produce false negative results especially in 
endemic Africa where P. falciparum is the dominant species and HRP2 based tests are 
used for diagnosis (48,68). Also some of the tests especially those based on detection of 
HRP2 remain persistently positive even after clearance of parasitemia, which has been 
attributed to persistence of antigens and presence of gametocytes, making these tests 
unsuitable for use in treatment monitoring. (62,69–71). Their performance may be 
affected by storage conditions such as temperature and humidity (72). Despite these 
problems, RDTs still provide a better chance of extending diagnostic services to areas 
where microscopy is not available (19). 
 
Previously, RDTs were relatively more expensive, and they were not considered cost 
effective for widespread use during the era of chloroquine and sulfadoxine-
pyrimethamine (17,35,73). However, costs of RDTs have gone down, expensive 
antimalarial drugs in the form of ACTs are in use, and the contribution of malaria as a 
cause of fever has gone down, making RDTs to be seen as cost effective tools for 
directing treatment. 
 
 
Summary: Characteristics of malaria parasite based tests 
The following table (Table 1) summarises some of the characteristics of laboratory 
based tests discussed.   
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Table 1: Performance characteristics of malaria diagnostic tests 
 
VARIABLE GSM AO PCR LAMP HRP2 LDH 
Equipment Simple Simple Sophisticated Moderate None None 
Expertise Moderate Moderate High Moderate Low Low 
Cost Low Moderate high Moderate Moderate Moderate 
Lab requirement Yes Yes Yes, hi tech Yes No No 
Detection level 50-100/µL 100p/µL <1-5p/µL <1-5p/µL  100p/µL 100p/ µL 
Time to results 45min-1h 20min >2hr <1hr 10-20min 10-20min 
Sensitivity High High Very high Very high  Moderate Moderate 
Specificity High Low Vey high Very high Low High 
Species detection Yes Poor Yes Yes Possible Possible 
Quantification Yes Poor No No No No 
Treatment 
monitoring 
Yes No Yes Yes No Yes 
GSM = Giemsa stained microscopy AO = Acridine orange PCR = Polymerase chain reaction LAMP = 
loop-mediated isothermal amplification HRP2 = Histidine rich protein LDH = lactate dehydrogenase 
 
 
1.2.3 Malaria diagnosis and treatment guidelines 
 
Antimalarial drugs 
Antimalarial drugs have different points of action on the life cycle of the parasite. The 
most commonly used drugs act on the erythrocytic stage of the parasite, preventing a 
clinical disease or curing an established one. They are usually referred to as blood 
schizontocidal drugs and include chloroquine (CQ), quinine (QN), amodiaquine (AQ), 
mefloquine, lumefantrine and artemisinin drugs (74,75). Chloroquine was the most 
widely used drug for treatment of uncomplicated malaria up to the 1980s, as is still 
effective against non-falciparum infections. In those areas where P. falciparum parasite 
developed resistance to chloroquine, which include all of sub Saharan Africa, the drug 
has been replaced with artemisinin combination therapies (ACT) (1). Quinine is usually 
used for treatment of severe or complicated malaria. Other drugs act on pre-
erythrocytic stages, gametocytes and hypnozoites. These drugs prevent invasion of 
erythrocytes, transmission and relapses. 
 
Since malaria is an acute and potentially fatal disease, its treatment should be based on 
drugs that are effective at killing the parasites and are affordable. Chloroquine was an 
effective, safe and cheap drug, and the development of resistance to the drug raised 
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global concern about antimalarial drug use. One of the strategies being advocated is the 
use of combination therapies, especially those based on artemisinins (ACT) (11). The 
principle behind combination therapy is that the chance of parasite resistant mutations 
simultaneously developing against two drugs with different mechanisms of action is 
very low (11,75).  
 
Malaria diagnosis and treatment guidelines 
According to the WHO, the objective of producing malaria treatment guidelines is to 
provide global, evidence-based recommendations on the treatment of malaria (11). The 
guidelines provide a framework for development of country specific guidelines. The 
first edition of the WHO malaria treatment guidelines was produced in 2006, at a time 
when resistance to chloroquine and sulfadoxine-pyrimethamine had reached very high 
rates, and its consequences on morbidity and mortality recognised (11). The main 
recommendation was the use of ACT for treatment of uncomplicated malaria. 
Following the release of these guidelines, malaria endemic countries started changing 
treatment policies to ACT. However, diagnostic approaches remained the same, based 
mainly on clinical symptoms and clinical algorithms.  
 
As increasing evidence became available of a reduction in the contribution of malaria 
as a cause of fever and the safety of withholding treatment to parasite negative patients 
including children, the second edition of the guidelines was produced in 2010. The 
guidelines recommend that all patients suspected to have malaria should be tested, and 
treatment with ACT be confined to parasite positive patients (16,19). It is 
recommended that RDTs be used as diagnostic tools in areas where microscopy in not 
available or its quality guaranteed.  It is also emphasized that ACTs should be used for 
treatment of uncomplicated malaria, and artemisinins should not be used as 
monotherapies. 
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1.3 THE TANZANIAN CONTEXT 
In Tanzania, 90% of the population is at risk of malaria, and there are 11 million 
clinical episodes annually. Malaria is still one of the leading causes of morbidity and 
mortality. P. falciparum is responsible for over 90% of all malaria incidence in 
Tanzania, where the main vectors are Anopheles gambiae s.l, A. arabiensis and A. 
funestus.  The coastal areas of Tanzania have the highest endemicity of malaria. Recent 
publications are showing a decline in the burden of malaria in Tanzania (76,77). Data 
from the Tanzania Demographic and Health Survey (DHS) is also showing a decline in 
the burden of malaria in some areas, e.g. in Ifakara where the prevalence of malaria has 
declined from 35% in 2000 to 10% in 2008 (78). 
 
1.3.1 The health care system 
The health care system in Tanzania is categorized into four levels: (1) the home or 
community, (2) the dispensary, (3) the health centre and (4) the hospital. At the 
community level there is a village health post supposed to be run by Community health 
workers (CHW). Many of them function on an ad hoc basis. There are two CHWs per 
village, one male and another female, although additional CHWs may be recruited 
depending on need. CHWs are not normally involved in curative services. Their main task 
is in preventive services, health education, child growth monitoring and follow-up of 
patients at home (HIV/AIDS, TB/Leprosy and other chronic conditions).  
 
At the ward level there is a dispensary that caters for about 3-5 villages with a catchment 
population of about 10,000 people. A dispensary is normally run by one clinical officer and 
one public health nurse. At the level of division, there is a health centre that serves a 
catchment population of about 50,000 people. In addition to outpatient services offered at 
the dispensary level, the health centres also offer laboratory and in-patient services. The 
health centre staff includes several assistant medical officers (AMO)/clinical officers (CO), 
enrolled nurses and medical attendants.  
 
On the top of the hierarchy are the hospitals - district hospitals, regional hospitals and 
referral hospitals, each serving as a referral facility for the lower level health facilities. The 
staffs at district hospitals include medical officers, and the facilities have larger inpatient 
and laboratory capacities. They offer a broad range of services including diagnostic 
services, blood transfusion and surgery. Regional hospitals are higher up with specialists in 
each department and more diagnostic and treatment capacity. Referral hospitals receive 
patients from regional and district hospitals that need specialist diagnostic and treatment 
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services not available at lower levels. They also serve as teaching hospitals. The referral 
system is however flexible such that patients from lower levels can be referred to higher 
levels where appropriate treatment is available, e.g. from dispensary to district level for 
blood transfusion services. 
 
1.3.2 Malaria control in Tanzania 
Malaria control in Tanzania is based on four strategies, namely malaria case 
management based on the use of RDTs and ACT, and the use of LLNS, IRS and 
Intermittent preventive treatment in pregnancy (IPTp). The case management strategy 
is explained in the next section. The use of treated mosquito nets has been advocated 
for a long time. A subsidized voucher system for treated nets was established in 2004 
for pregnant women and in 2006 for infants. More recently, a large campaign to 
distribute free LLNs to all children under five years of age was implemented in 2010, 
followed by universal coverage of all households in 2011 mainly implemented through 
donor funds. Another strategy, IRS is undertaken in high malaria transmission areas, 
especially around Lake Victoria and other epidemic prone areas. According to the 
HIV/Malaria Indicator survey of 2012, 91% of households own at least 1 ITN, an 
increase from 23% in 2004/2005; and 14% of households had been sprayed in the last 
12 months prior to the survey with higher rates of between 40% and 92% in high 
transmission and epidemic prone areas (79). 
 
Pregnant women are at increased risk of getting infected due to lowered immunity 
during pregnancy. When malaria parasites infect the placenta, they cause effects on the 
pregnancy outcome and growth of the foetus, which may end up in abortion, still birth, 
low birth weight and maternal anaemia (80). In order to reduce serious consequences of 
malaria during pregnancy, in addition to the LLNs, IPTp is given to pregnant women 
during routine antenatal clinic visits. It involves the administration of at least two 
therapeutic doses of an antimalarial drug; in this case sulfadoxine-pyrimethamine (SP) 
at least one month apart, starting in the second trimester.  The first dose is given 
between 20-24 weeks and the second at 28-32 weeks of pregnancy. A recent report 
indicated that only 33% of women took two or more doses of SP during their last 
pregnancy and were considered protected (79), and stock outs of SP are reported to be 
common.  
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1.3.3 Malaria diagnosis and treatment guidelines 
The malaria situation in Tanzania has undergone rapid changes in recent years. Prior to 
the year 2000, malaria diagnosis was mainly based on clinical features, and chloroquine 
was the drug of choice for over 40 years (81). Widespread resistance of parasites to CQ 
lead to resurgence of malaria, with an increase in morbidity and mortality due to 
malaria. Malaria endemic countries were eventually forced to change treatment policies 
in favour of more effective antimalarial drugs. Tanzania is one of the countries that 
within a short time span revised its malaria diagnosis and treatment guidelines, 
changing the first line drug from CQ to SP in 2001 when resistance to CQ had reached 
60% (81), and eventually to ACT in 2007 when  resistance to SP reached an average of 
25% (82). 
 
The guiding principle of the new national malaria treatment guideline is to provide safe, 
effective, good quality and affordable drugs to those who need them, yet at the same 
time encourage rational drug use, which will minimize the development of drug 
resistance. Early and correct diagnosis is therefore essential in the effort to encourage 
rational use of antimalarials and in ensuring that other causes of fever are properly 
managed to reduce severe morbidity and mortality.  
 
Up to early 2009, 83% of health facilities in Tanzania had no laboratory capacity for 
malaria diagnosis. In other places microscopes were available but results inaccurate, 
leading to misdiagnosis and overuse of ACT. The country started introducing RDTs at 
all health facility levels in 2009 in line with the WHO recommendation, directing that 
all patients suspected to have malaria be tested before treatment (16,19). The RDT roll 
out was completed in 2012. The algorithm for the use of RDTs in Tanzania (Figure 3) 
shows steps by step instructions in deciding when to test and action following results of 
the test at different levels of health care (83). Emphasis is also placed on investigating 
for other causes of fever even when the test for malaria is positive so that other causes 
of fever or co-morbidities can also be properly managed.   
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Figure 3: Algorithm for the use of malaria RDT.  
 
 
Clinically suspected malaria 
(Based upon history and physical 
examination)
No
Yes
NoYes
Treat immediately 
with parenteral 
antimalarial and 
antibiotic
PRIMARY AND SECONDARY LEVEL
PRIMARY LEVEL SECONDARY LEVEL
mRDT and/or BS
positive
mRDT and BS
negative
SEVERE DISEASE
Malaria not likely
Continue parenteral antibiotics
Repeat mRDT and BS within
 6-24 hours if malaria still 
suspected
SEVERE MALARIA
 
Continue parenteral 
antimalarials and 
antibiotics
SEVERE DISEASE
STOP antimalarials
Continue antibiotics and 
other supportive care
SEVERE MALARIA
Continue parenteral 
antimalarials and 
antibiotics
mRDT and/or BS
positive
mRDT and BS 
negative
mRDT/BS negativemRDT/BS positive
UNCOMPLICATED 
MALARIA
Treat with antimalarial 
Investigate other 
causes of fever
NON-MALARIAL 
FEBRILE ILLNESS
Do NOT give antimalarial
Investigate other causes 
of fever
Ask the patient to return in 
2 days if not improved
Danger signs 
present?
Do NOT 
perform mRDT
Perform mRDT/BS
Refer immediately 
to secondary level
Admit and perform 
mRDT and BS
 
 
Source: Learners’ manual for Malaria rapid diagnostic test. Final draft (83). 
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1.4 CHALLENGES IN MANAGING MALARIA 
1.4.1 Prompt access to treatment and rational use of drugs 
During the last years there has been a decrease in both morbidity and mortality due to 
malaria in many African countries following combined interventions with ACT for 
treatment, insecticide treated nets (ITN) and IRS (2,84,85). In areas where these 
interventions have been successful, surveillance is becoming increasingly important. 
Early and prompt parasite based diagnosis is essential in order to target ACT to 
patients with confirmed malaria infection, prevent overuse of ACTs, reduce costs and 
to minimize development and spread of antimalarial drug resistance (86). 
Furthermore, in areas where elimination of malaria is considered feasible, an optimal 
surveillance is critical to assure effective malaria control, to detect upcoming 
epidemics and to identify and contain remaining cases. 
 
Early diagnosis and prompt treatment with effective drugs is an important strategy to 
reduce morbidity and mortality due to malaria. In view of the fact that malaria 
recognition and treatment occurs at home and is often inadequate, Heads of State of 
African countries made a commitment to ensure at least 60% of patients suffering 
from malaria should have prompt access to treatment within 24 hours of the onset of 
symptoms by the year 2005 (87), later raised to 80% by 2010. In settings with limited 
access to health care, strategies to improve access at community level are needed.  
 
Home management of malaria is recommended by the WHO and has been used on a 
large scale in some countries (88,89). Previous studies on home management of malaria 
were based on clinical diagnosis, which meant that all children with fever were treated 
with antimalarial drugs. With the use of ACT for home management of malaria, the 
challenge is to increase access to effective drugs while targeting treatment to malaria 
patients only and achieving high compliance (90).  
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ACTs are highly efficacious, with very high cure rates. The combination of two drugs 
with different modes of action helps to achieve high cure rates and delay the 
development of parasite resistance. In this way, the therapeutic life of the drug is 
prolonged. However, ACTs are more expensive than previously used drugs (CQ and 
SP). The introduction of ACT brought challenges to the health care system. Overuse of 
the drug will impose a heavy burden on the health budget of poor developing countries 
and may facilitate development of parasite resistance to the drugs. There are already 
indications of selection of parasites during treatment with ACT (91,92) and decreased 
parasite drug susceptibility to ACT in South East Asia, which calls for strategies to 
improve diagnosis at all health care levels to restrict treatment to confirmed malaria 
patients. 
  
Apart from its role in limiting resistance development, appropriate malaria diagnosis is 
part of good clinical practice as it helps in the overall management of the patient, by 
identifying patients with malaria to receive antimalarial drugs, and those without 
malaria who also deserve to be appropriately managed (19). 
  
While microscopy of giemsa stained blood smears is the gold standard method for 
diagnosis of malaria, maintaining quality has been a challenge as it requires qualified 
and experienced personnel, equipment and supplies, which are often lacking in health 
facilities in endemic areas. The availability of RDTs malaria offers a suitable 
alternative especially in areas where microscopy is not available, or its quality cannot 
be guaranteed. They are an important tool to ensure that malaria diagnosis is available 
even in peripheral areas with limited resources. 
  
Non adherence to test results have been reported in several studies, with up to 50% of 
RDT negative patients were still given antimalarial drugs (93–95). Low testing rates 
have also been reported, meaning underutilisation of testing facilities (96,97).  Non 
adherence to test results is not limited to RDT, but was also seen with microscopy 
(98,99). However, other studies have shown opposite results with high adherence to test 
results and reduction in prescriptions of ACTs (100–103). In these studies, overall 
health outcome of fever patients improved after RDT use, probably because of 
improved management of non malarial fevers. 
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Increased efforts in malaria control which includes widespread use of ITN, IRS and 
ACT, are leading to a reduction in the proportion of malaria among fevers, making the 
extent of over-diagnosis and overtreatment even worse. Reduction in the malaria 
burden, with lower prevalence has been reported in several countries including 
Tanzania  (2,76). With a decline in the malaria burden it becomes even more important 
to use parasitological diagnosis to restrict treatment to malaria positive cases only. With 
the availability of evidence of the safety of withholding treatment to parasite negative 
children (104), the WHO is now recommending universal testing of all fever cases 
before prescription with antimalarial drugs (16). 
 
1.4.2 Use of RDTs in endemic areas 
The National Malaria Control Program (NMCP) in Tanzania has rolled out RDTs as 
diagnostic tools in health facilities in the country with funding from the Global Fund. 
Rollout started in three pilot regions in June 2009 and by December 2012, all regions 
had been covered. According to the NMCP, test kits are available in all government 
health facilities and used as routine diagnostic tests. HRP2 based tests were introduced 
following the recommended by WHO that where more than 95% of the infections are 
due to P. falciparum infections, HRP2 based tests should be used. 
 
An issue of concern with the HRP2-based tests is the finding of persistent antigen, 
causing false positive results for up to several weeks after successful treatment 
(71,105). In endemic areas where the possibility of new infections within a short time 
period exist, when patients return with symptoms after a recent antimalarial treatment 
it is not possible to differentiate between RDT positivity due to persisting antigens 
from a previous infection and actual parasitemia caused by treatment failure or re-
infection. The low specificity of HRP2-based tests is a problem especially in high 
transmission areas (106) as it could lead to antimalarial treatment in non malarial 
patients and affects health workers adherence to results and reliance in new diagnostic 
tools. On the other hand the LDH-based RDTs are more specific since LDH is only 
produced by live parasites and does not persist after parasite clearance (107). It has 
therefore been suggested that LDH based tests would be more useful for follow-up 
after treatment to assess cure and clearance of malaria infection. Beside the problem 
with persisting antigens, presence of gametocytes can also give rise to false positive 
result, both for HRP2 and LDH based tests. Since ACTs are also effective against 
gametocytes, false positivity due to gametocytes has become less of an issue (108).   
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No previous study has comprehensively investigated the correlations between detection 
and clearance of whole parasites, parasite DNA and antigens using two different 
microscopic techniques (Giemsa stained thick films and acridine-orange stained thin 
films), PCR for DNA detection and two different RDTs (HRP2 and LDH based) during 
42 days follow up after initiation of ACT treatment in children with uncomplicated P. 
falciparum malaria residing in a high endemic area. 
 
1.5 RATIONALE FOR THE STUDY 
Increased efforts in malaria control interventions have lead to the reduction in the 
contribution of malaria as a cause of fever. With this reduction, continued reliance on 
clinical symptoms as a basis for treatment of malaria in endemic countries will lead to 
overtreatment & irrational use of antimalarial drugs, increasing drug pressure and hence 
resistance development to the available drugs, and negatively affecting the health of the 
patient as the actual cause of fever will not be identified and treated 
 
The availability and use of diagnostics is therefore an important aspect in the 
management of patients with fever. Not only is it important in rational use of 
antimalarial drugs, but is essential for overall patient management as it allows for other 
causes of fever to be investigated and appropriately treated.  
 
The studies described in this thesis were aimed at assessing the impact of improving 
malaria diagnosis at health facility and community level on antimalarial prescriptions 
and health outcome, and the utilization of malaria diagnostics for patient follow up after 
treatment. Findings from these studies have policy implications by providing 
information on the impact of diagnostics on antimalarial prescription practices, safety 
of using CHWs and RDTs for malaria management at community level, on the role of 
RDTs for patient follow-up and other operational issues of RDT/diagnostics 
implementation.   
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2 AIMS AND OBJECTIVES 
2.1 General aim 
To assess the impact of laboratory diagnosis towards improving the management of 
uncomplicated malaria at peripheral health care (PHC) settings in Coast region, 
Tanzania. 
 
2.2 Specific objectives 
1. To assess the impact of malaria diagnosis training at health facility level on 
antimalarial drugs prescription and health outcome (Study I). 
2. To assess the impact of CHWs using RDTs for uncomplicated malaria at 
community level on antimalarial drugs prescriptions and health outcome 
(Study II).  
3. To assess current malaria diagnostic and prescription practices following the 
introduction of malaria RDTs in peripheral health care facilities (Study III). 
4. To assess initial clearance and detection of recurrent P. falciparum as 
determined by microscopy, HRP2 and LDH-based RDTs, and PCR 
following treatment with ACT in Tanzanian children with uncomplicated 
malaria (Study IV). 
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3 MATERIAL AND METHODS 
 
3.1 Study sites and study population 
 
All the studies were conducted in Bagamoyo and Kibaha districts, Coast Region, 
Tanzania. Coast region is found along the coastal belt, which is a high malaria 
transmission area. The area experiences two rain seasons, the long rains in March-June 
and short rains in October-December. Transmission follows the rainfall pattern, with 
peak in May-July and December-January. According to the National Census of 2002, 
Bagamoyo and Kibaha districts had a population of 230,164 and 132,045, respectively, 
with 20% of the population under the age of five years (109). Malaria was the leading 
cause of outpatient attendance, hospital admissions and deaths. 
 
Figure 4: Map showing location of Coast region and study districts in Tanzania 
 
 
 
 
 
 
Study I was conducted in 2004 at sixteen PHC facilities in the two districts, at a time 
when SP was the first line drug for treatment of uncomplicated malaria. Study II was 
conducted in 2006 at community level in five villages in Kibaha district, when the 
home management strategy was advocated to facilitate early treatment, just before the 
replacement of SP with ACT as first line treatment for uncomplicated malaria. Study III 
was conducted in 2011 at ten PHC facilities, one year after introduction of RDT in 
Kibaha district. Study IV was conducted from 2009 to 2011 at two PHC facilities, one 
in Bagamoyo and the other one in Kibaha district. The study population for study I and 
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IV was children under five years of age, while for study II and III it was patients of all 
ages. 
 
 
3.2 STUDY I: THE IMPACT OF IMPROVING MALARIA DIAGNOSIS AT 
PHC FACILITIES  
This was a cluster randomised intervention trial testing two intervention packages. 
Sixteen PHC facilities were involved, 10 of them were in Bagamoyo district (Chalinze, 
Fukayosi, Hondogo, Kiwangwa, Lugoba, Matuli, Mbwewe, Msata, Msoga and Msata) 
and six in Kibaha district (Kikongo, Mbwawa, Mlandizi, Mwanabwito, Ngeta and 
Visiga). The facilities were stratified by previous exposure to IMCI training and 
randomly allocated to either training on clinical algorithm and microscopy (arm I),  
clinical algorithm only (arm II) or no training (control, arm III). Arms I and II had 5 
PHC facilities each while arm III had 6. The intervention package included group 
training of all cadres of health workers on clinical and/or laboratory diagnosis with 
theoretical and practical demonstration depending on intervention arm. The training 
programme was developed and implemented by researchers from the Muhimbili 
University of Health and Allied Sciences (MUHAS) malaria project.  
 
Children under five years of age with fever or history of fever, without symptoms of 
severe disease, making the first consultation for the current illness were included in the 
study after getting consent from parents or guardians. Patients records, including 
symptoms, tests performed and results as well as treatment prescribed were recorded in 
the case record forms (CRF). All patients were requested to attend a day 7 follow-up. 
They were also encouraged to come back any time if the fever persisted or the 
condition worsened. During these visits, the patients’ health status was assessed, 
additional medication prescribed if indicated and blood smears collected on day 7.  
 
In the microscopy intervention arm, blood smears were collected from all patients on 
day 0 and 7. They were stained with giemsa and examined by health workers at the 
facility, with a second reading done at MUHAS. From the other intervention arms, 
blood slides were only collected on day 7, and these were examined at MUHAS. 
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The impact of the intervention was evaluated by assessing the prescription rate of 
antimalarial drugs, antibiotics and health outcome on day 7 across the different arms of 
the intervention. 
 
3.3 STUDY II: THE USE OF MALARIA RDTS BY COMMUNITY HEALTH 
WORKERS TO GUIDE TREATMENT AT COMMUNITY LEVEL 
In view of the introduction of ACT in Tanzania, and the drive towards home 
management of malaria, we evaluated the possibility of using CHWs with the aid of 
RDTs for diagnosis to increase access to antimalarials at community level.  
 
This was an intervention study with a cross over design. The study was performed in 
five villages (Kikongo, Mbwawa, Miswe, Mwanabwito and Ngeta) in Kibaha District, 
Twenty two Community Health Workers (CHWs) were involved in the study, and the 
number of CHWs selected per village ranged from 2-5, depending on the village 
geography and population size, each CHW being responsible for between 300 and 500 
people. The intervention included training of CHWs on malaria diagnosis with or 
without the use of RDTs, together with the provision of the test kits for malaria 
diagnosis and ACT for treatment of uncomplicated malaria in the community. The 
training package included general knowledge on malaria, symptoms of severe disease, 
and symptoms of other diseases presenting with fever. They were instructed to refer 
patients with symptoms of severe disease or non malarial illnesses to health facilities 
for further management.  They were also oriented to practical issues of testing and data 
handling including patient follow up planned for day 3 and 7.  
 
The inclusion criteria were fever or history of fever within the last 24 hours, without 
symptoms of severe disease; while patients aged less than 3 months old and pregnant 
women were excluded from the study.  
 
During implementation, CHWs changed the diagnosis method alternating between 
RDT and clinical diagnosis from one week to another. RDTs were performed according 
to manufacturer’s instructions (Paracheck Pf, Orchid Biomedical Systems, India). 
Included patients were to be treated with ACT if RDT results were positive during 
RDT weeks, or if they had symptoms suggestive of malaria during CD weeks. The 
ACT (artemether-lumefatrine, Coartem) was administered at doses recommended by 
the manufacturer according to age (Novartis, Switzerland). Only the first dose of ACT 
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was given under supervision. If malaria was not diagnosed or suspected, or patients had 
symptoms suggestive of another cause of fever they were referred to health facilities for 
further management.  
 
The effect of RDTs on prescription of ACT and health outcome was assessed. The 
main outcome variable was ACT prescriptions. Secondary outcome variables included 
health outcome by day 7, the proportion of patients getting treated within 24 hours of 
onset of fever, and compliance to treatment. 
 
3.4 STUDY III: DIAGNOSIS AND PRESCRIBING PRACTICES 
FOLLOWING INTRODUCTION OF RDTS 
 
The study was conducted in Kibaha district, one of the first districts in Tanzania to 
introduce RDTs for malaria diagnosis in 2009.  Ten out of 25 eligible PHC facilities 
were randomly selected and included in the cross-sectional study. These were Kikongo, 
Kongowe, Mbwawa, Misugusugu, Miswe, Mwanabwito, Mwendapole, Ngeta and 
Ruvu station dispensaries, and Mlandizi health centre. The aim of this study was to 
identify malaria diagnosis and treatment practices after introduction of RDT as 
diagnostic tools at PHC facilities. The study also looked at health workers attitudes and 
perceptions about testing and their influence on practice. 
 
Questionnaires were administered as interviews to health care providers attending 
patients with fever. These were used to collect information on their knowledge, 
attitudes and prescription practices in relation to malaria diagnostics. Exit interviews 
were also conducted with fever patients, and in the case of children with their 
caretakers, and information collected included their presenting symptoms, tests 
performed, test results, prescribed drugs and their knowledge about malaria testing. A 
health facility inventory was also undertaken and included interview with the person in 
charge of the facility and review of routine health facility records. The aim of the 
inventory was to collect information on staffing, availability of diagnostics (RDT and 
microscopy), supplies and essential drugs; and the malaria situation over the last one 
year. 
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3.5 STUDY IV: CLEARANCE AND DETECTION OF RECURRENT 
PLASMODIUM FALCIPARUM FOLLOWING TREATMENT WITH ACT 
 
This was a descriptive, exploratory study conducted at two health facilities, Fukayosi 
dispensary in Bagamoyo district and Mlandizi health centre in Kibaha district, to 
assess the performance of different malaria diagnostic tests in the follow up of 
patients with uncomplicated malaria treated with ACT. Children under five years of 
age (6-59 months) with uncomplicated malaria, P. falciparum mono-infection and 50-
6,250 asexual parasites/200 white blood cells (wbc) equivalent to a parasite density of 
2000-250,000/uL attending the PHC facilities were enrolled into the study. Treatment 
with ACT was initiated on day of enrolment. 
 
Patients were followed up over a 42 day period (day 1, 2, 3, 7, 14, 21 28, 35 and 42) 
and we assessed the clearance of malaria parasites, antigen and DNA and detection of 
recurrent infection using RDTs (HRP2 and pLDH based), microscopy (giemsa stain 
and acridine orange) and PCR using blood samples collected on filter paper.  Patients 
were also followed up clinically for re-appearance of fever. All clinical and 
demographic information, including age, sex, temperature and symptoms at 
presentation (day 0) and on follow up dates, prescribed drugs (day 0 and afterwards) 
and information on use of ITNs was recorded in a CRF.  
 
During follow up visits, a blood smear was examined at the health centre and results 
used to guide treatment if the patient complained of fever. The Giemsa stained thick 
blood smears and acridine orange stained smears from enrolment and follow up visits 
were examined at MUHAS and Muhimbili National Hospital (MNH) experienced 
microscopists. Quality control of slide reading was done at Karolinska Institutet (KI), 
Sweden. RDTs were performed according to manufacturer’s instructions at the health 
facilities.  
 
DNA was extracted from blood spots collected on filter papers (and if necessary on 
used RDTs) at the Malaria research unit of Karolinska Institute (KI), Sweden. The PCR 
analysis was performed using a P. falciparum specific method targeting the 18S rRNA 
gene as previously described (110). A subset of samples with a fixed volume on the 
filter paper were analyzed with quantitative PCR (111,112). In case of recurrent 
parasitemia during follow up stepwise genotyping of three highly polymorphic genetic 
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markers, i.e. the merozoite surface protein 1 and 2 as well as glutamine rich protein, 
was performed according to standard protocols to differentiate re-infections from 
recrudescence (44). 
 
Table 2: Summary of methodologies for the studies included in this thesis 
 
 Study I Study II Study III Study IV 
Study design Randomised 
controlled  
intervention trial 
(3 arms) 
Cross over 
intervention study 
(2 arms) 
Cross-sectional 
descriptive study 
Exploratory 
descriptive study 
Intervention 
package 
Training of PHC 
facility staff on 
clinical algorithm 
and microscopy 
Training of CHW 
on malaria 
diagnosis using 
clinical and RDTs 
NA NA 
Study population Children <5 years 
of age with fever 
Patients of all ages 
with fever 
Patients of all ages 
with fever 
Children <5 years 
of age with fever 
and Pf mono-
infection 
Sample size 3131 patients 2930 patients 195 patients,  
20 PHC workers, 
10 PHC facilities 
53 patients 
Data collection Recording of signs 
and symptoms by 
PHC staff, 
Interview with 
mother or 
guardian, 
Microscopy of 
blood smear for 
malaria parasites 
Recording of signs 
& symptoms by 
CHW, 
Interview with 
patient, mother or 
guardian, 
Testing for 
malaria by RDT  
Exit interviews 
with patients, 
Interviews with 
PHC facility 
workers, 
PHC facility 
inventory 
 
Recording of signs 
and symptoms, 
Laboratory tests at 
enrolment and 
follow up – 
microscopy, RDT, 
PCR (sample 
collected on filter 
paper) 
Follow up Up to day 7 Up to day 7 None On 9 occasions up 
to day 42 
Outcome variables Positivity rate, 
Prescriptions of 
antimalarials and 
antibiotics, and 
health outcome by 
day 7 
Positivity rate, 
Prescriptions of 
antimalarials & 
health outcome by 
day 7 
Testing rates, 
Positivity rate, 
Prescriptions of 
antimalarials & 
antibiotics  
Clearance times 
for parasites, 
antigen  and DNA, 
Detection of 
recurrent infection 
 
 
3.6 ETHICAL CONSIDERATIONS 
These studies received ethical approval from the National Institute for Medical 
Research (NIMR) (study I) or the MUHAS Research and Publication Committee in 
Tanzania  (studies II-IV), and from Karolinska Institutet/Regional Ethics Committee, 
Stockholm, Sweden for studies I, II and IV). 
 
In addition to that, permission to conduct the study was obtained from district 
authorities, health facilities and village administration. Informed consent was obtained 
from health workers and patients and caretakers/guardians in case of children who 
participated in the studies.  
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4 RESULTS 
 
4.1 STUDY I: THE IMPACT OF IMPROVING MALARIA DIAGNOSIS AT 
PHC FACILITIES 
A total of 3131 children were included in the three arms of the study.  In the 
microscopy intervention arm (arm I), 531/973 (54.6%) of children tested positive for 
malaria by PHC microscopy. Antimalarial drugs were prescribed to 576 children (61%) 
in arm I, 1008/1058 children (95.3%) in arm II (clinical) and to 1091/1100 children 
(99.5%) in arm III (control). Non compliance to test results was observed in arm I, with 
11.3% of patients with negative results being given antimalarial drugs. 
 
Overall, antibiotics were prescribed to 44.8% of all patients, and the rate did not differ 
significantly between the three arms with 45.9%, 54.8% and 34.2% of patients getting 
antibiotics in arms I, II and III respectively. Patients with positive malaria test results 
were less likely to be prescribed antibiotics than those with negative results. 
 
The sensitivity and specificity of PHC microscopy when compared to expert 
microscopy were 74.5% and 59.0% respectively. The accuracy of microscopy varied 
between PHC facilities, with sensitivity increasing with parasite density.  
 
When looking at health outcome by day 7, there was no difference in the proportion of 
patients reporting full recovery by day 7, with rates of 74.4%, 78.6% and 67.6% for 
arms I, II and III respectively. 
 
Expert microscopy reading of day 0 slides from arm I revealed that 76 patients with 
positive results did not receive antimalarial drugs. Fourteen of the patients came back 
with symptoms between days 1 and 3 and were successfully treated. In the remaining 
patients, the fever resolved but parasitemia was cleared after getting antimalarial drugs. 
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4.2 STUDY II: THE USE OF MALARIA RDTS BY COMMUNITY HEALTH 
WORKERS TO GUIDE TREATMENT AT COMMUNITY LEVEL 
Twenty two CHWs from 5 villages were involved in the study. A total 2930 patients 
(760 children under five years) were included in the study during the 5 months study 
period. Attendance to the CHW was not influenced by presence of RDT as only 1457 
(49.7 %) patients came to the CHW on a week when RDT was used for diagnosing 
malaria. The proportion of patients consulting the CHW within 24 hours of onset of 
fever was similar for the RDT and CD groups, with 67.3% and 68.4% respectively. 
 
When using RDTs for malaria diagnosis, 50.3% (733/1457) of patients tested positive 
for malaria.  Positivity rate was highest in the 5-9 year age group and lowest in those 
above 15 years. With clinical diagnosis 91.6% (1415/1473) were classified as malaria 
and there was no difference by age.  
 
ACT (artemether-lumefantrine) were given to 53.2% (775) of patients during the RDT 
weeks compared to 96.5% (1422) of patients during the CD week, OR= 0.04 (p < 
0.001). The reduction in ACT drug prescriptions was most prominent in patients 15 
years (57.3 % reduction) and lowest in the age range 5-9 years. Forty four (6.1%) RDT-
negative patients were also given malaria treatment.  
 
The health status on day 7 was evaluated for 2869/2930 (97.9%) patients. Full recovery 
was reported by 2735 (93.3%) of all patients. The proportion reporting full recovery 
among patients seen during the RDT week was 93.3% as compared to 97.3% from the 
CD week. There were no reports of severe disease or death among patients not treated 
with ACT during RDT weeks.  
 
The number of patients given referral to the health facility from day 0-7 was 250 
(17.2%) from the RDT group compared to 73 (5%) from the CD group. In both groups, 
referrals were more common among patients who did not receive ACT. 
 
Deaths among patients within 28 days of inclusion were actively investigated. Three 
children died, all within 3 days of their inclusion into the study. Two of them (1 RDT 
positive, 1 CD, both BS positive) were treated with ACT and referred to PHC facilities 
for management of other conditions. The third child with both RDT and BS negative 
was not treated with antimalarials but referred. One adult also RDT and BS negative 
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died within 7 days of inclusion. The patient was referred to the PHC facility for 
management of other conditions.  
 
RDT positivity was higher than BS positivity, at 50.3% vs. 22.6%. The quality of the 
slides was poor. Agreement between the 1
st
 (field) and 2
nd
 reader (expert, MUHAS) 
was 0.85 and the kappa coefficient was 0.59. 
  
4.3 STUDY III: DIAGNOSIS AND PRESCRIBING PRACTICES 
FOLLOWING INTRODUCTION OF RDTS 
Ten health facilities were involved in the study, one of which was a health centre and 
the rest were dispensaries. A health facility inventory revealed stock outs of both RDTs 
and ACT in 5 and 4 out of the 10 facilities respectively. Three of the facilities without 
RDTs were using microscopy, leaving two facilities without any malaria testing.  
 
One hundred and ninety five patients of all ages (and guardians in case of children) 
were involved in the exit interview. Among them, 45% were children under five years 
of age and 55% were aged above 5 years. The testing rate in facilities with diagnostics 
was low as only 105/168 (63%) of patients were tested with either RDT or BS. The 
testing rate was significantly higher among children under five years of age than among 
older children and adults. Among tested patients, 31 (30%) were positive, and the 
positivity rate did not differ by age. Lack of diagnostic facilities as evidenced by stock 
outs of RDTs was the main reason for the low testing rate. 
 
Antimalarial drugs were given to all patients with positive results, and to 10/74 (14%) 
of patients with negative results, and there was no difference in antimalarial 
prescription by age. The overall prescription rate among non tested patients was 28% 
(25/90), with a higher rate among patients in facilities without diagnostics (70%, 
19/27). Antibiotics were prescribed to 76% of patients, and the rate was higher among 
patients with negative malaria tests results compared to those with positive results (81 
vs. 69%, p<0.01) and among patients not tested compared to those tested for malaria 
(84 vs. 69%, p=0.01). Due to stock outs of ACT, some 18% of patients were prescribed 
non ACT drugs, mainly SP and QN. 
  
Twenty health workers were interviewed, among them 12 had clinical training 
background and the rest were non-clinical.  The majority of health workers (18/20) had 
 34 
been trained on RDT use. Reasons given by health workers for prescribing antimalarial 
drugs to patients with negative results included not trusting RDT results (“false 
negative”) and the presence of clinical symptoms suggestive of malaria, and patients 
with negative results responding to antimalarial drugs. A few patients did not trust 
negative RDT results, mainly because they were given positive results at private 
dispensaries, and they did not get an alternative diagnosis. 
 
The utility of routine HF records was limited by poor record keeping, as data was often 
incomplete and was not compiled on a regular basis. 
 
Table 3: Summary of results from studies on diagnosis and treatment practices (Studies 
I-III) 
 Study I Study II Study III 
 Arm Ia Arm 
II
b
 
Arm 
III
c
 
RDT CD With  
diagnostics 
Without 
diagnostics 
Total no. of patients 973 1058 1100 1457 1473 168 27 
Malaria testing 
       
Tested for malaria 973   1457  105  
(63%) 
 
With positive results 531 
(55%) 
  733 
(50%) 
 31  
(30%) 
 
Antimalarial drugs 
       
All patients  571 
(61%) 
1008 
(95%) 
1091 
(99%) 
775 
(53%) 
1422 
(97%) 
47 
(28%) 
19 
(70%) 
Test negative patients 50/442 
(11%) 
  44/682  
(6%) 
 10/74 
(14%) 
 
Antibiotic drugs 
       
All patients 434 
(46%) 
593 
(55%) 
375 
(34%) 
  127/168 
(76%) 
21/27 
(78%) 
Tested patients      72/105 
(69%) 
 
Positive malaria test  36%     12/31 
(39%) 
 
Negative malaria test 58%     60/74 
(81%) 
 
Non tested      55/63 
(87%) 
 
Arm I
a
: clinical algorithm and microscopy  
Arm II
b
: clinical algorithm only  
Arm III
c
: no training (control) 
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4.4 STUDY IV: CLEARANCE AND DETECTION OF RECURRENT 
PLASMODIUM FALCIPARUM FOLLOWING TREATMENT WITH ACT 
Fifty three children completed the 42 day follow-up period and were included in the 
analysis. There were 35 (66%) males and 18 (34%) females, with mean age 42 months  
(range 10 – 59). All the children had a fever history of 1 to 4 days duration (mean 2.4 
days).  At the time of enrolment, 44 children (83%) had a fever in the range of 37.5°C 
to 39°C.  Apart from fever, other symptoms reported were vomiting (42%), cough 
(26.4%), abdominal pain (17%) and diarrhea (7.5%). All the children were prescribed 
artemether-lumefantrine, the first line antimalarial drug. Other medication prescribed 
were antipyretics (94%), antibiotics (11%) and oral rehydration solution (ORS) (7%). 
 
Median clearance times for all tests are based on the 53 children, except for HRP2 
which is based on 43 children without re-infections. The majority of children cleared 
their parasitemia within 2 days as assessed by PCR and microscopy. Median clearance 
times for pLDH and HRP2 based tests was 7 (2-14) and 28 (7-42) days respectively. 
There were 10 re-infections during the follow-up period; 1 on day 14, 4 on day 21, 2 on 
day 28 and 3 on day 35. At the time of the recurrent infection, the HRP2 test was still 
positive in 8 of these patients. Due to longer clearance times, the HRP2 based test was 
able to identify recurrent malaria infection in only 2 of the cases, and these were in 
patients who had cleared their initial antigenemia. On the other hand, the LDH based 
test identified 8 of the recurrent infections on the day of occurrence and the 9
th
 at the 
next follow up visit. PCR was able to identify all ten recurrent infections while 
microscopy identified 8 of the cases. Figure 5 is showing positivity for malaria 
parasites, antigen and DNA at follow-up days.  
 
Figure 5: Comparison of different tests positivity on follow-up days 
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5 DISCUSSION 
In order for malaria patients to be appropriately treated, there is need for parasite-based 
diagnostics to be made as early as possible after onset of symptoms, preferably in the 
community or at the lower levels of health care, and results be used to guide treatment. 
 
Findings from our study at community level (study II) show that malaria can be safely 
managed at community level by CHWs equipped with easy to use diagnostics in the 
form of RDTs and ACTs (113). RDT based diagnosis reduced the prescription of 
antimalarial drugs by 45%.  With more than 60% of patients seeking treatment within 
24 hours of onset of fever, progression to severe disease may be arrested. There was no 
indication of severe malaria in patients with negative results and not treated with ACT, 
which shows that the use of RDT results to direct treatment did not affect the health of 
patients with negative results similar to findings in other studies (104,114). Findings 
from this study are supported by a recent review which shows that community based 
programmes with free or subsidized antimalarial drugs are likely to improve access to 
antimalarial drugs, and that RDTs can be safely used to reduce overuse of antimalarial 
drugs (115).   
 
As malaria symptoms resemble those of other diseases with fever as the cardinal 
symptom, and with the possibility of co-infections, it is important to emphasize the 
need for thorough assessment of the patient to identify other causes of fever or co-
morbidities. When health workers focus on results of malaria testing and forget about 
other causes of fever, there is a possibility of missing and not treating potentially 
serious infections with dire consequences on the health of the patient (20,116,117). In 
our study (study II), CHWs were trained to identify and refer other causes of fever, 
even among ACT treated patients. In this way, other diseases requiring antibiotic 
treatment (e.g. pneumonia) will be attended at the health facility and avoid the danger 
of complete reliance on malaria test results.  
 
Improved diagnosis through training and use of microscopes at health facilities is also 
important (study I), and was found to reduce antimalarial treatment from 96.5% to 61% 
(118). The poor quality of health facility microscopy which was partly associated with 
the short training period in our study is a common finding in resource poor settings 
(119). Due to the possibility of missed infections where the quality of microscopy 
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cannot be guaranteed or false negative RDT results, close follow-up of patients should 
be part of the management plan for patients with negative results.  
 
In order for malaria testing to have an impact on antimalarial prescriptions and 
treatment outcome, health workers must adherence to test results by restricting malaria 
treatment to patients with positive results only. In our studies, non adherence was also 
observed with 11%, 6% and 14% of patients with negative results treated with 
antimalarial drugs in the first three studies (113,118,120). These results were similar to 
findings from other recent studies which in addition to reduction in antimalarial 
prescriptions also showed improved health outcome (100–102), and were much lower 
than previous studies reporting up to 50% of patients with negative results treated with 
antimalarials (93,94,121,122).  
 
Among factors identified as cause for non adherence to treatment guidelines are prior 
training, previous guidelines, interaction with others, experience and patient demand 
for antimalarials (123–126). A recent qualitative study in Ghana showed that patients 
expected RDTs to diagnose not only malaria, but any cause of their illness (127), and 
were disappointed when told they were negative for malaria without an alternative 
diagnosis. Health workers in the study area (study III) had used RDTs for more than a 
year, and they may have acquired experience and confidence with test results (120). 
Lack of trust by some of the health workers as well as lack of trust and demand for 
antimalarials by patients was reported. Under such circumstances, and in the absence of 
alternative diagnosis for the cause of fever, antimalarial drugs will continue to be 
prescribed, with delays in the treatment of other causes of fever. The availability of 
diagnostics, training and drugs for the management of other causes of fever help will to 
eliminate the problem (19,128). Training should also emphasize the actions in the 
algorithm which allow treatment of negative patients only in case the patient is a child 
under five with no possibility for follow up. The low testing rates in facilities with 
diagnostics has also been observed elsewhere (96,97), and in our study it was attributed 
to limited supplies of test kits and staff shortage.  
 
Poor record keeping observed in most of the facilities means that data on prevalence of 
malaria and consumption of diagnostics and drugs is not available or of poor quality. 
Such data cannot be used for planning and forecasting of supplies and surveillance; and 
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could be an important factor in the stock outs observed. The importance of correct and 
timely record keeping should be emphasized during training and supervision.  
 
High prescriptions of antibiotics were found in two of our studies (113,118). A study in 
Dar es Salaam also found that antibiotic prescriptions increased from 49 to 72% after 
introduction of RDTs especially among patients with negative malaria test results 
(D’Acremont et al. 2011). It was not in the scope of our studies to identify other causes 
of fever, and for that reason we cannot say if the antibiotic prescriptions were justified 
or not. 
 
The higher sensitivity of HRP2 based tests in detecting P. falciparum infections and 
lower cost were the main reason for choice of these tests for diagnosis of malaria in 
Africa. However, persistence of antigen after treatment has also been observed in 
several studies (71,105,107,129). This is a problem in endemic areas where the 
possibility of re-infections within a short period exists and there is a need to 
differentiate positivity due to persisting antigens and that due to recurrent infections 
(71,130). In our study on antigen clearance (study IV) we also found a high re-infection 
rate with 10 out of 53 turning positive within a 42 day follow up period, and because of 
prolonged antigenemia, the HRP2 test could not detect 8 of the infections. On the other 
hand, the LDH based test performed better and could be useful for patient follow up 
after treatment. The logistics of managing two types of RDTs, HRP2 based for initial 
testing due to high sensitivity, and LDH test for follow-up after treatment due to high 
specificity needs to be considered. Microscopy of giemsa stained blood smears 
performed well in this respect, and strengthening this service at health facilities could 
provide a good tool for patient monitoring after treatment and for quality control of 
RDTs. 
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6 CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Conclusions 
Overall conclusion 
Training and provision of diagnostics at community and health facility level 
reduces unnecessary use of antimalarial drugs and allows for early diagnosis and 
management of non malarial fevers. Due to longer persistence of HRP2 antigen in 
blood, HRP2 based tests performed poorly in patient follow up and detection of re-
infections when compared to LDH based tests. 
Study specific conclusions: 
 Training of health care workers and use of microscopy for malaria diagnosis at 
health facilities reduced the prescription of antimalarial drugs by restricting 
treatment to test positive patients (study I). 
 RDTs in the hands of CHWs can help to direct treatment with antimalarial 
drugs within the community, increasing prompt access to the drugs while 
limiting unnecessary use (study II). 
 The use of malaria RDTs at community level was safe as no fatal or severe 
disease occurred among patients who did not get antimalarial drugs because of 
negative test results (study II). 
 Even after adoption of the universal testing policy of all fever patients, low 
testing rates were observed, caused by irregular supply or non-availability of 
testing facilities (RDT and microscopy) and staff shortage (study III). 
 Although non adherence to negative test results is still practiced, the rates 
observed in our studies (Studies I – III) were low, ranging from 6 to 14%. The 
main reasons for the practice were health workers not trusting RDT results and 
limited ability to diagnose and treat other causes of fever. 
 Persistence of the HRP2 antigen makes tests based on this antigen unsuitable 
for patient follow-up after treatment and detection of reinfections, whereas 
LDH based tests are more suited for this purpose (study IV). 
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6.2 Recommendations  
 The implementation of the universal testing policy is hampered by RDT 
stock-outs. There is need to strengthen forecasting and procurement to ensure 
constant availability of test kits. 
 Non adherence to test results still exists although at a lower rate when 
compared to previous studies, and several factors were identified as being 
responsible for this practice in the cross sectional survey. Equipping health 
workers with knowledge, skills and facilities to be able to diagnose and 
manage other causes of fever will help to build their confidence in RDT 
results and increase their compliance. In-depth studies should also be 
conducted on health system and other factors affecting health worker 
prescription practice. 
 HRP2 based RDTs are highly sensitive for diagnosis of P. falciparum 
infections. These advantages are set back by antigen persistence, which makes 
the tests unsuitable for patient follow up. Other tests, such as LDH based RDTs 
should be considered for this purpose. However, the logistics of handling two 
types of tests from procurement, training and supervision of health workers 
should be taken into account.  
 The quality of microscopy at PHC facilities was low. Good quality microscopy 
is essential for correct diagnosis and post treatment evaluation of patients with 
malaria. There is need to strengthen microscopy services, which can be used for 
treatment monitoring in severe cases, patient follow-up after treatment and 
quality control of RDTs. 
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